ACM
PCRX icon

Archon Capital Management’s Pacira BioSciences PCRX Stock Holding History

Archon Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-536,525
Closed -$15.7M – 31
2024
Q1 		$15.7M Buy
+536,525
New +$16.5M 5.41% 5

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Archon Capital Management's PCRX Position: Q2 2024 in Review

Archon Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2024, closing a stake of 536,525 shares — an estimated $15.7M sold.

Archon Capital Management first reported a position in PCRX in Q1 2024 and held it in 1 quarter. The position peaked at $15.7M in Q1 2024. 280 funds tracked by Wall St. Rank hold PCRX as of Q2 2024.

  • Archon Capital Management reported no remaining Pacira BioSciences position as of Q2 2024 after selling out during the quarter.
  • Archon Capital Management sold 536,525 Pacira BioSciences shares in Q2 2024, an estimated $15.7M.
  • Archon Capital Management first reported a position in Pacira BioSciences in Q1 2024 and held it in 1 quarter.
  • Archon Capital Management's Pacira BioSciences position peaked at $15.7M in Q1 2024.
  • 280 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2024.

Based on Archon Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.